Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
25.93 EUR | -1.08% | -2.17% | -22.94% |
11:55am | Bayer: further positive results in menopause | CF |
10:10am | Bayer's Elinzanetant Reduces Menopausal Symptoms in Late-stage Trial | MT |
Sales 2024 * | 47.31B 51.31B | Sales 2025 * | 48.53B 52.63B | Capitalization | 25.75B 27.93B |
---|---|---|---|---|---|
Net income 2024 * | 2.26B 2.45B | Net income 2025 * | 3.63B 3.94B | EV / Sales 2024 * | 1.24 x |
Net Debt 2024 * | 32.98B 35.77B | Net Debt 2025 * | 29.8B 32.32B | EV / Sales 2025 * | 1.14 x |
P/E ratio 2024 * |
12.1
x | P/E ratio 2025 * |
7.35
x | Employees | 96,931 |
Yield 2024 * |
0.71% | Yield 2025 * |
3.07% | Free-Float | 99.97% |
Latest transcript on Bayer AG
1 day | -1.40% | ||
1 week | -2.57% | ||
Current month | -8.12% | ||
1 month | -10.69% | ||
3 months | -19.83% | ||
6 months | -47.25% | ||
Current year | -23.25% |
Managers | Title | Age | Since |
---|---|---|---|
William Anderson
CEO | Chief Executive Officer | 57 | 23-03-31 |
Wolfgang Nickl
DFI | Director of Finance/CFO | 54 | 18-04-25 |
Bijoy Sagar
CTO | Chief Tech/Sci/R&D Officer | 55 | 20-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Colleen Goggins
BRD | Director/Board Member | 68 | 17-03-31 |
Director/Board Member | 68 | 17-03-31 | |
Alberto Weisser
BRD | Director/Board Member | 68 | 21-03-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
9.77% | 70 M€ | -.--% | - | |
5.71% | 2 M€ | +13.56% | - | |
4.28% | 962 M€ | -.--% | - | |
4.10% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-19 | 25.92 | -1.14% | 2 183 570 |
24-03-18 | 26.22 | -0.08% | 2,958,874 |
24-03-15 | 26.24 | +0.81% | 9,539,161 |
24-03-14 | 26.02 | -1.27% | 3,608,300 |
24-03-13 | 26.36 | -0.49% | 3,351,866 |
Delayed Quote Xetra, March 19, 2024 at 06:41 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-23.25% | 28B | |
+30.83% | 687B | |
+30.67% | 595B | |
+0.01% | 378B | |
+15.18% | 316B | |
+11.39% | 308B | |
-0.06% | 211B | |
-6.97% | 208B | |
-3.83% | 203B | |
-3.72% | 157B |